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Objective: We sought to compare 10-year survival in patients after mitral valve
replacement with biologic or mechanical valve prostheses.
Methods: Retrospective survival analysis was performed on data from 1139 con-
secutive patients older than 18 years of age undergoing mitral valve replacement
with Carpentier-Edwards (n = 495; Baxter Healthcare Corp, Irvine, Calif) or St Jude
Medical (n = 644; St Jude Medical, Inc, St Paul, Minn) prostheses.
Results:  The 10-year survival was not statistically different between the patients
receiving Carpentier-Edwards valves and those receiving St Jude Medical valves (P
= .16). Adjusted survival estimates at 2, 5, and 10 years were 82% ± 2% (95% con-
fidence intervals, 79%-85%), 69% ± 2% (95% confidence intervals, 64%-73%), and
42% ± 3% (95% confidence intervals, 37%-48%), respectively, for the Carpentier-
Edwards group and 83% ± 2% (95% confidence intervals, 80%-86%), 72% ± 2%
(95% confidence intervals, 69%-76%), and 51% ± 3% (95% confidence intervals,
45%-58%), respectively, for the St Jude Medical group. Predictors of worse survival
after mitral valve replacement are older age, lower ejection fraction, presence of
class IV congestive heart failure, coronary artery disease, renal disease, smoking
history, hypertension, concurrent other valve surgery, and redo heart surgery.
Conclusion: Choice of biologic or mechanical prosthesis does not significantly
affect long-term patient survival after mitral valve replacement.
The advantages and disadvantages of mechanical valve prostheses andbioprostheses have been known to us since the beginning of the firstsuccessful implantation of a valve prosthesis. Mechanical valveprostheses were first implanted in 1960, 6 years before the first bio-prostheses were routinely used.1,2 Because of the risk of throm-boembolism and the hazards of continuous anticoagulation associat-
ed with mechanical valve prostheses, tissue valves were widely used for mitral
valve replacement from the 1970s until the early 1980s.3 However, one disadvan-
tage of the bioprostheses was predictable structural failure, often leading to reoper-
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ation, whereas mechanical valves provided durability. As a
result, an increased preference for mechanical valve pros-
theses was observed after 1983. Currently, the use of bio-
prostheses has decreased to less than one third of the total.4
The above information indicates that many physicians
and patients after 1983 prefer mechanical valve prostheses.
The 2 randomized clinical trials5,6 on comparison of
mechanical valve prostheses and bioprostheses conducted in
the 1970s and early 1980s support the acceptability of either
valve type, with comparable 10-year mortality and valve-
related complications between the 2 valve groups. However,
the valve models tested in these 2 randomized trials are sel-
dom used now, and no subsequent large-scale randomized
trials have compared biologic and mechanical prostheses.
A number of recent articles have supported the use of bio-
prostheses. For example, Myken and associates7 reported that
bleeding was more hazardous than reoperation. Fradet and
colleagues8 suggested that bioprostheses reduced the overall
rate of postoperative valve-related complications. Cobanoglu
and coworkers9 stated that successful reoperations should not
be considered as treatment failure, and Holper and associ-
ates10 argued that reoperation on bioprostheses seemed not to
be a significant risk for patients 65 years or older.
Although we can debate whether reoperation is more
hazardous than having increased risks of strokes and hem-
orrhage, long-term mortality should be an important criteri-
on for comparison of the 2 valve types, if not the most
important one. The objective of this article is to compare
long-term survival in patients who undergo mitral valve
replacement in a more recent time frame. The present study
examines the 2 most current and widely used stent-mounted
porcine xenografts and bileaflet mechanical prostheses in
regard to long-term survival. Valve-related complications
will be addressed in a future study because of constraints on
the length of this article.
Methods
This study is based on data from 1139 consecutive patients greater
than 18 years of age undergoing mitral valve replacement with 1 of
2 prostheses between 1976 and 1995 at Duke University Medical
Center. The patient population contains 495 patients with the
Carpentier-Edwards (CE) standard porcine prosthesis (model 6625;
Baxter Healthcare Corp, Irvine, Calif) and 644 patients with the St
Jude Medical (SJ) prosthesis (model M101; St Jude Medical, Inc,
St Paul, Minn). Patients receiving other prostheses were excluded
from analysis.
Patient Population
Selection of a mechanical SJ or a porcine CE prosthesis is deter-
mined by patient preference and by surgeon judgment on the basis
of patient age and comorbidities, including illness predisposing to
bleeding, and patient lifestyle, including history of compliance
with anticoagulant therapy.11 Because the advantage of mechanical
valves is extended durability, patients with a long life expectancy
after the operation are usually given a mechanical valve. As Czer
and coworkers12 mention, “The selection process has resulted in
mechanical and bioprosthetic valve recipients who form two dis-
tinctly different patient populations.”
At our center, the CE biologic valve prosthesis was implanted
starting in 1976, whereas the SJ mechanical valve prosthesis was
first implanted in 1983. As a result, there are different follow-up
times for the recipients of the 2 types of prostheses. For example,
the median follow-up time is 12 years for the CE group and 6 years
for the SJ group; the maximum follow-up time is 21 years for the
CE group and 15 years for the SJ group. Data analysis therefore
has to address potential selection biases, including differing years
of operation and follow-up times and changes in operative tech-
niques and medical care practice.
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TABLE 1. Distribution of demographic and medical history
variables by valve type (all patients)
CE (n = 495) SJ (n = 644) P value
Age (y)* 62 (52-69) 61 (50-69) .327
Male sex 42% 33% .001
Ejection fraction* 50 (44-59) 54 (46-61) .001
Atrial fibrillation 53% 56% .242
Coronary disease 31% 29% .352
Liver disease 4% 2% .097
Lung disease 14% 18% .080
Renal disease 6% 4% .311
NYHA class IV 40% 54% .001
Diabetes 10% 14% .063
Hypertension 36% 45% .001
Smoking history 43% 41% .654
Redo heart surgery 17% 27% .001
Mitral stenosis 42% 49% .01
Regurgitation grades 79% 74% .073
3 and 4
Year of operation* 1982 (1979-1986) 1990 (1988-1993) .0001
NYHA, New York Heart Association.
*Median (interquartile range).
TABLE 2. Distribution of valve cause by valve type
Cause CE (n = 495) SJ (n = 644) P value
Ischemic 10% 7% .147
Prolapse 23% 15% .001
Rheumatic 36% 41% .087
Perivalvular leak/ 7% 17% .001
prosthetic dysfunction
Calcific 7% 3% .001
Congenital 1% 1% .675
IHSS 1% 1% .184
Infectious 4% 4% .841
Other* 5% 7% .098
Missing 6% 4% .141
IHSS, Idiopathic hypertrophic subaortic stenosis.
*Degenerative and other category.
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Demographics, clinical characteristics, and surgical procedure
information on patients undergoing valve replacement at Duke
University Medical Center were retrospectively extracted from the
prospectively collected Duke patient medical records and the com-
puterized Duke patient database. The predictor variables collected
for this analysis include 2 types of variables. The continuous
numeric variables include age, ejection fraction, and date of opera-
tion. The categoric variables indicating presence of disease include
atrial fibrillation, coronary artery disease, diabetes, liver disease,
lung disease, renal disease, hypertension, smoking history, redo
heart surgery, concomitant valve surgery, acute presentation at the
time of the operation, mitral stenosis, and mitral insufficiency.
Other categoric variables of nominal or ordinal characteristics are
causes of the mitral valve disease and congestive heart failure class.
Prognostic variables are defined as clinical diagnoses (Table 1).
Renal disease was defined as a serum creatinine level of 2.0 mg/dL
or greater. Redo heart surgery is defined in this article as any prior
cardiac operation, including aortic, mitral, or tricuspid replacement
or repair or coronary artery bypass grafts. Concomitant valve
surgery is defined in this article as concomitant aortic valve
replacement or tricuspid valve repair or replacement along with the
present mitral valve replacement. All disease variables are coded
as 1, representing the presence of the disease, and 0, representing
the absence of the disease.
Medical history variables and baseline characteristics of this
patient population were extracted from medical records into a data-
base, and follow-up telephone interviews were conducted on a
yearly basis. Patient follow-up information regarding survival sta-
tus was obtained by use of telephone interview (65%), medical
records (28%), and the National Death Index (7%). As of March
1999, the survival status of 96% of the patients was known.
Survival time was calculated from the date of patient valve replace-
ment to the date of patient death, loss to follow-up, or last follow-
up. Patients lost to follow-up or still alive as of March 1999 were
censored at the date last seen.
The distributions of continuous predictor variables within valve
type are described with medians and interquartile ranges.
Dichotomous predictor variables are described with proportions.
Statistical comparisons of the 2 patient groups on these predictors
are performed with the use of the Mann-Whitney U test for contin-
uous variables and the Pearson χ2 test for dichotomous variables.
In the analysis of our observational data, one potential problem
is that differences in long-term survival demonstrated by the unad-
justed raw survival estimates may be due to assignment of valve
type on the basis of prognostic factors. Multivariate regression
modeling in the Cox survival model with propensity score used as
a covariate is performed to assess the effect of valve type on the
probability of survival after mitral valve replacement. The incor-
poration of a propensity score balances the weight of covariates
between the 2 valve types on each patient level so that comparisons
of these 2 groups of patients are more meaningful.13,14
The assumption of proportional hazards is checked for all prog-
nostic variables listed in Table 1 with the use of diagnostics on the
basis of weighted residuals.15 Univariate survival analysis is car-
ried out for each of the predictor variables in Table 1. Stepwise
regression analysis with the forward selection and backward elim-
ination technique is used to select significant variables for inclu-
sion in a final model from the list of predictor variables in Table 1.
Hazard ratios and 95% confidence intervals (CI) are provided. The
Kaplan-Meier method is used to generate unadjusted raw survival
curves for the 2 valve groups. The log-rank statistic is reported for
the comparison of the unadjusted survival curves. The α level for
univariate and multivariable comparisons is set at .05. SAS soft-
ware, version 6.12 (SAS Institute, Inc, Cary, NC), was used to per-
form all statistical analyses and graphics.
Survival according to valve type is compared in all patients with
CE or SJ prostheses, including all operation years between 1976 and
1995. We refer to these data later as the all-patients data set. To
address the issue of different distributions of date of operation in the
CE and SJ groups, we performed a second analysis in a subset of
patients with years of operation after 1983 when both CE and SJ
prostheses were used. This is the data set that we refer to later as the
patients-after-1983 data set. The same list of prognostic variables
provided in Table 1 is used for generating final survival models for
both the all-patients and patients-after-1983 data sets.
To check whether one valve type is associated with sicker patients,
we compared operative mortality or 30-day mortality percentages for
Figure 1. Unadjusted 10-year survival curves of the SJ group and
the CE group, with patient numbers remaining at risk given at 2, 4,
6, 8, and 10 years after the operation. The data set was all patients.
Figure 2. Adjusted 10-year survival curves of the SJ group and the
CE group, with patient numbers remaining at risk given at 2, 4, 6,
8, and 10 years after the operation. The data set was all patients.















the 2 patient groups. Logistic regression is used to test for predictors of
30-day survival. To cover for the possibility that the operating room
techniques could have improved since 1990, we use date of operation
as a dichotomous variable (before 1990 vs after 1990) to test the effect
of valve type on operative or 30-day mortality.
Younger and Older Patients
To explore the common assumption that younger patients should
receive mechanical prostheses and older patients should receive bio-
logic prostheses, we tested the interaction between age group (<60
years vs ≥60 years) and valve model. Separate survival analyses
were also carried out in the younger patient population (age <60
years) and in the older patient population (age ≥60 years) by using
the statistical methods described above. The year of age cutoff (60
years) is based on clinical relevance with consideration of compara-
ble number of patients in each subgroup. To answer possible ques-
tions regarding elderly patients, we also compare survival of the 2
valve groups in patients 70 years or older at the time of operation.
Results
All Patients
The CE and SJ recipient groups are not statistically differ-
ent in terms of age, coronary disease, atrial fibrillation, liver
disease, lung disease, renal disease, diabetes, smoking his-
Surgery for Acquired Cardiovascular Disease Cen et al
TABLE 3. Results of univariate testing (all patients)*
Variable P value Hazard ratio Lower Upper
Age (10-y increment) <.0001 1.37 1.27 1.47
Male sex .009 1.24 1.06 1.46
Ejection fraction (10% lower) <.0001 1.20 1.11 1.30
Atrial fibrillation .665 1.04 0.88 1.22
Coronary artery disease <.0001 2.12 1.79 2.51
Liver disease .017 1.61 1.09 2.39
Lung disease .002 1.39 1.13 1.70
Renal disease <.0001 2.98 2.20 4.05
Congestive heart failure, class IV <.0001 1.70 1.44 2.00
Diabetes .0002 1.55 1.23 1.95
Hypertension <.0001 1.50 1.27 1.76
Smoking history .093 1.15 0.98 1.35
Redo heart surgery <.0001 1.52 1.26 1.83
Concomitant valve surgery .003 1.3 1.10 1.57
Acute presentation <.0001 1.62 1.32 2.00
Valve cause (9 degrees of freedom)† .05
Mitral stenosis .035 0.84 0.72 0.99
Mitral insufficiency grade 3 and 4 .41 1.09 0.89 1.34
Valve prosthesis .006 0.79 0.66 0.93
Year of operation .85 1.00 1.00 1.00
*Results from univariate testing are the unadjusted raw results not taking into consideration possible confounding effects of other parameters.
†Valve cause with 9 degrees of freedom was not tested for hazard ratio and 95% CI.
TABLE 4. Variables in the final survival model using propensity score (all patients)
Variable P value Hazard ratio Lower Upper
Valve type (1 = SJ, 0 = CE) .155 0.83 0.64 1.07
Score* .156 0.77 0.53 1.11
Age (10-y increment) .0001 1.31 1.21 1.42
Ejection fraction (10% lower) .001 1.14 1.05 1.23
Coronary artery disease† .0001 1.65 1.37 1.99
Concomitant valve surgery† .001 1.37 1.14 1.66
Redo heart surgery† .0001 1.69 1.38 2.08
Renal disease† .0001 2.21 1.59 3.08
Lung disease† .022 1.28 1.04 1.6
Congestive heart failure, class IV† .0001 1.57 1.32 1.87
Hypertension† .009 1.27 1.06 1.51
*Propensity score that reflects the probability of being assigned to the mechanical valve group.
†1 = yes, 0 = no.
Cen et al Surgery for Acquired Cardiovascular Disease


















tory, or mitral regurgitation (Table 1). However, the CE
group has worse ejection fraction, higher percentage of
acute presentation at the time of the operation, and earlier
year of operation. The SJ group has a higher proportion of
hypertension, mitral stenosis, and redo heart surgery.
Valve cause (Table 2) is predominantly rheumatic, and it
is equally distributed in the 2 patient groups. There is a
higher percentage of paravalvular leak/prosthetic dysfunc-
tion in the SJ group (17%) than in the CE group (7%),
whereas a higher percentage of mitral prolapse is observed
in the CE group (23%) than in the SJ group (15%).
All variables from Table 3 were checked for the assump-
tion of proportional hazards by using the weighted residual
technique.15 A global test of proportional hazards on all
these variables was nonsignificant (P = .16). Individual tests
on each variable showed that valve type meets the propor-
tionality assumption (P = .56), as do the other variables,
except for age, which showed a minor deviation from pro-
portional hazards (P = .02). Allowing age to reflect its non-
proportionality by dichotomizing it did not affect the sur-
vival result.
Univariately, significant predictors of worse survival are
CE valve type, older age, male sex, lower ejection fraction,
presence of coronary artery disease, lung disease, liver dis-
ease, renal disease, congestive heart failure class IV, dia-
betes, hypertension, redo heart surgery, concomitant other
valve surgery, acute presentation, and mitral stenosis (Table
3). Unadjusted raw survival curves comparing the 2 valve
types are presented in Figure 1.
Absolute 30-day mortality is not different between the 2
valve types: 12.5% (62/495) for CE recipients and 10.4%
(67/644) for SJ recipients (P = .3). Independent predictors
of increased 30-day mortality are age (P < .0001), redo heart
surgery (P = .001), renal disease (P < .0001), absence of
mitral prolapse (P = .006), and whether the year of opera-
tion was before 1990 (P = .001). Valve type (CE vs SJ) is not
an independent predictor of 30-day mortality in the cohort
of all patients (P = .9).
By means of the logistic model, important variables that
predict the assignment of valve type are age (P < .0001),
concomitant other valve surgery (P = .0008), atrial fibrilla-
tion (P = .013), mitral stenosis (P < .0001), class IV con-
gestive heart failure (P = .012), hypertension (P = .049), and
date of operation (P < .0001). The propensity score (0-1)
generated from the logistic model is the probability of being
assigned to the mechanical valve group.
The prognostic variables from Table 1 that enter the
final model are listed in Table 4. Controlling for these
covariates, valve type does not predict survival (P = .16).
Significant predictors of worse survival are older age,
lower ejection fraction, presence of coronary artery dis-
Figure 3. Adjusted 10-year survival curves of the SJ group and the CE
group, with patient numbers remaining at risk given at 2, 4, 6, 8, and
10 years after the operation. The data set was patients after 1983.
Figure 4. Adjusted 10-year survival curves of the SJ group and the
CE group in all patients less than 60 years of age, with patient
numbers remaining at risk given at 2, 4, 6, 8, and 10 years after the
operation. The data set was all patients.
Figure 5. Adjusted 10-year survival curves of the SJ group and the
CE group in all patients age 60 years or older, with patient num-
bers remaining at risk given at 2, 4, 6, 8, and 10 years after the
operation. The data set was all patients.















ease, lung disease, renal disease, class IV congestive heart
failure, hypertension, redo heart surgery, and concomitant
other valve surgery (Table 4). Adjusted survival estimates
at 2, 5, and 10 years are 82% ± 2% (95% CI, 79%-85%),
69% ± 2% (95% CI, 64%-73%), and 42% ± 3% (95% CI,
37%-48%), respectively, for CE recipients and 83% ± 2%
(95% CI, 80%-86%), 72% ± 2% (95% CI, 69%-76%), and
51% ± 3% (95% CI, 45%-58%), respectively, for SJ recip-
ients. Figure 2 shows the adjusted survival curves of the 2
valve groups.
Patients After 1983
In this cohort of patients (n = 869), the 2 patient groups are
statistically different in terms of several variables (Table 5).
The SJ recipients (n = 644) statistically differ from the CE
recipients (n = 225) in age, male percentage, ejection fraction,
class IV congestive heart failure, atrial fibrillation, coronary
disease, liver disease, redo heart surgery, mitral stenosis,
mitral insufficiency grade 3 and 4, and date of operation.
By means of the logistic model, younger age (P < .0001),
concomitant other valve surgery (P = .0008), atrial fibrilla-
tion (P < .0001), class IV congestive heart failure (P = .015),
and later date of operation (P < .0001) are associated with
the assignment of SJ valve type. The prognostic variables
from Table 1 that enter the final survival model are listed in
Table 6. Controlling for those covariates, valve type does
not predict survival (P = .18) in this subset of patients (Table
4). The result confirms our earlier results from all patient
data sets. Figure 3 shows the survival curves of the 2 valve
groups in patients after 1983.
Younger and Older Patients
There is no significant interaction between patient age cate-
gory (<60 vs ≥60 years) and valve type (CE vs SJ).
However, for clinical insights, we compared the 10-year sur-
vival of the CE and the SJ recipients in a younger patient
population and in an older patient population by using the
data set of all patients.
For younger patients, age less than 60 years (n = 527), the
CE recipients (n = 222) statistically differ from the SJ recip-
ients (n = 305) in terms of greater percentage of male sub-
jects, lower ejection fraction, less class IV congestive heart
failure, less mitral stenosis, and earlier date of operation
(Table 7). Significant predictors in patients age less than 60
years are class IV congestive heart failure (P < .0001),
hypertension (P < .0001), coronary artery disease (P <
.0001), redo heart surgery (P = .001), and renal disease (P =
.0007). Adjusting for the significant prognostic variables,
valve prosthesis is not a significant predictor of survival in
the younger patients (P = .16, Figure 4).
For older patients, age greater than 60 years (n = 612),
the CE recipients (n = 273) are not statistically different
from the SJ recipients (n = 339) in terms of age, male per-
centage, ejection fraction, atrial fibrillation, coronary dis-
ease, liver disease, lung disease, renal disease, diabetes,
smoking history, and mitral insufficiency. CE recipients
differ from SJ recipients in terms of less class IV conges-
tive heart failure, less hypertension, less redo heart surgery,
and earlier year of operation (Table 8). Significant predic-
tors in patients age 60 years or greater are class IV conges-
tive heart failure (P < .0001), coronary artery disease (P =
.012), redo heart surgery (P < .0001), diabetes (P = .048),
and history of smoking (P = .008). Controlling for the sig-
nificant prognostic variables, valve prosthesis is not a sig-
nificant predictor of survival in patients age 60 years or
older (P = .74, Figure 5).
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TABLE 5. Distribution of demographic and medical history
variables by valve type (patients after 1983)
CE (n = 225) SJ (n = 644) P value
Age (y)* 68 (60-73) 61 (50-69) .0001
Male sex 40% 33% .037
Ejection fraction* 51 (42-61) 54 (46-61) .0012
Atrial fibrillation 46% 56% .006
Coronary disease 42% 29% .001
Liver disease 4% 2% .246
Lung disease 18% 18% .965
Renal disease 7% 4% .107
NYHA class IV 42% 54% .004
Diabetes 13% 14% .797
Hypertension 43% 45% .517
Smoking history 42% 41% .940
Redo heart surgery 19% 27% .024
Mitral stenosis 31% 49% .001
Regurgitation grade 74% 56% .001
3 and 4
Year of operation* 1986 (1984-1990) 1990 (1988-1993) .0001
NYHA, New York Heart Association.
*Median (Q1, Q3).
TABLE 6. Variables in the final survival model using propen-
sity score (patients after 1983)
Hazard
Variable P value ratio Lower Upper
Valve type .187 0.84 0.64 1.09
Score* .014 0.42 0.21 0.84
Age (10-y increment) .0001 1.26 1.12 1.42
Ejection fraction (10% lower) .0001 1.2 1.1 1.32
Coronary artery disease .0004 1.52 1.21 1.92
Concomitant valve surgery .0008 1.53 1.19 1.97
Redo heart surgery .0001 1.7 1.33 2.16
Renal disease .0001 2.61 1.73 3.96
Congestive heart failure, .0001 1.64 1.3 2.08
class IV
*Propensity score that reflects the probability of being assigned to the
mechanical valve group.
Cen et al Surgery for Acquired Cardiovascular Disease



















In this article we have used multivariable modeling with the
incorporation of propensity scores to minimize the biases in
this observational study and have demonstrated that the
choice of biologic or mechanical valve prosthesis does not
significantly affect patient long-term survival up to 10 years.
A few recent studies specifically examined the CE or SJ
prosthesis individually. Fradet and associates8 reported a
52.3% survival at 10 years with CE in the mitral position.
Ibrahim and coworkers16 reported a 58.8% survival with SJ in
the mitral position at 10 years, whereas Khan and colleagues17
reported a 42% survival with SJ in the mitral position at 10
years. These reports compare well with the 10-year survival of
52% with SJ and 42% with CE in our current series.
Several other recent retrospective studies have directly
compared biologic and mechanical valve prostheses. Fradet
and colleagues8 provided a comprehensive comparison
between bioprostheses and mechanical prostheses in both
aortic and mitral positions and reported significantly better
10-year survival with porcine valves in the mitral position.
Fradet and colleagues had a large number of mitral patients
(n = 2030), with an approximate 10-year follow-up time for
bioprosthesis recipients and an 8-year follow-up time for
mechanical prosthesis recipients. However, their mechani-
cal series comprised 4 models, 2 of which are seldom used
today, and their biologic series comprised 2 models, CE
supra-annular and CE standard porcine bioprostheses. Czer
and colleagues12 reported no difference in survival between
the porcine and SJ valve recipients with follow-up times
limited to 5 years.
A few other articles have compared valve-related compli-
cations. Myken and colleagues7 compared long-term valve-
related complications in patients with mechanical versus bio-
logic valve prostheses and reported significantly less 10-year
valve-related mortality with porcine valves. However, Myken
and colleagues had a small sample size (n = 200) and did not
distinguish patients with valve replacement in aortic or mitral
positions. Cobanoglu and coworkers9 compared tissue and
mechanical valves using a patient-oriented definition of treat-
ment failure that included valve-related death or permanent
patient disability. The results demonstrate an advantage of
porcine valves over mechanical valves at 7 years. The contri-
butions of their study were using treatment failure as a mea-
surement criterion and being the first to suggest that success-
ful reoperation should not be considered treatment failure.
We think it is important to examine valve-related com-
plications, as well as long-term survival, when we compare
the CE and SJ recipients. However, because of complicated
statistical methods and subsequent lengthy explanations
relating to competing risk issues when we examine valve-
related complications, we have decided to focus on compar-
ison of long-term survival in the current study and will
address the issues of valve-related complications and quali-
ty of life of these patients in future studies.
A few articles have examined the role of age in selection
of valve prostheses. Holper and colleagues10 examined
patients 65 years or older who underwent isolated aortic,
mitral, or combined aortic and mitral valve replacement.
Their findings were that valve type does not affect survival
up to 15 years in the older patient population. Grossi and
TABLE 7. Distribution of demographic and medical history
variables by valve type (age <60 years)
CE (n = 222) SJ (n = 305) P value
Age (y)* 51 (43-56) 49 (41-55) .234
Male sex 45% 29% .001
Ejection fraction* 50 (43-56) 54 (47-61) .0005
Atrial fibrillation 50% 51% .773
Coronary disease 20% 17% .361
Liver disease 5% 2% .032
Lung disease 13% 15% .512
Renal disease 4% 5% .576
NYHA class IV 37% 49% .01
Diabetes 8% 11% .221
Hypertension 29% 33% .278
Smoking history 54% 48% .22
Redo heart surgery 23% 26% .33
Mitral stenosis 47% 58% .03
Regurgitation grade 76% 68% .104
3 and 4
Year of operation* 1980 (1979-1982) 1990 (1988-1992) .0001
NYHA, New York Heart Association.
*Median (interquartile range).
TABLE 8. Distribution of demographic and medical history
variables by valve type (age ≥ 60 years)
CE (n = 273) SJ (n = 339) P value
Age (y)* 68 (64-73) 68 (64-73) .763
Male sex 39% 36% .46
Ejection fraction* 50 (44-61) 54 (45-62) .154
Atrial fibrillation 55% 61% .151
Coronary disease 40% 39% .79
Liver disease 3% 3% .806
Lung disease 15% 21% .072
Renal disease 7% 4% .086
NYHA class IV 41% 58% .001
Diabetes 12% 16% .137
Hypertension 40% 54% .001
Smoking history 34% 35% .716
Redo heart surgery 12% 28% .001
Mitral stenosis 38% 43% .206
Regurgitation grade 81% 78% .395
3 and 4
Year of operation* 1984 (1981-1988) 1991 (1989-1993) .0001
NYHA, New York Heart Association.
*Median (interquartile range).















coworkers18 examined choice of mitral prostheses in
patients age 70 years or older. Their findings were that valve
type does not influence 10-year freedom from noncardiac
death. These findings support our conclusion that valve type
does not influence survival in younger or older patients.
Previous studies have examined determinants of survival
after mitral valve replacement. Teoh and colleagues19
reported age and left ventricular function as independent
predictors of postoperative survival after mitral valve
replacement, with a mean follow-up time of 2.7 years. Teply
and coworkers20 examined valve replacement procedures in
aortic (52%), mitral (34%) and double-valve (2%) and
triple-valve (2%) positions, with a mean follow-up time of
approximately 6 years. They reported recent year of opera-
tion, younger age, and female sex to be predictors of late
survival. Lee and Bay21 reported that risk factors change
with time. For long-term mortality, predictors were older
age, surgeon, mitral insufficiency, and earlier year of opera-
tion. Adbelnoor and colleagues22 reported that, among
patients with mechanical prostheses, male sex, greater New
York Heart Association class, mitral regurgitation, and rela-
tive heart volume were predictors of worse survival.
Our findings from our all patient data sets show older age,
lower ejection fraction, concomitant other valve surgery, redo
heart surgery, presence of coronary artery disease, renal dis-
ease, lung disease, class IV congestive heart failure, and
hypertension predict long-term mortality. Our results suggest
that valve type does not predict survival. The result from our
all patient data sets is confirmed by the subset analysis in
patients after 1983 only. Survival comparisons in the younger
(age <60 years) and older (age ≥60 years) populations fail to
suggest a difference in survival in younger or older popula-
tions because of valve prosthesis type.
The current study is the largest to compare the CE bio-
logic and the SJ mechanical valve prostheses with a 10-year
long-term follow-up time. Our study does not include multi-
ple biologic or multiple mechanical valve models and there-
fore provides a pure comparison of 2 of the most widely used
prostheses at the present time. Our survival analyses use the
technique of propensity score in the multivariable Cox pro-
portional hazards model and examine a large number of
explanatory variables (Table 3) that could affect the outcome
of survival. Our findings on long-term survival comparison
confirm the results from the 2 randomized trials. Our
exploratory survival analyses in the younger and older
patient populations suggest that prosthesis selection does not
affect long-term survival in younger or older patients.
Our study is limited by its retrospective nature and by the
shorter median follow-up time in the SJ group. A difference
in survival may be observed with a longer follow-up dura-
tion in the SJ group. At this point, the effect of prosthesis
type on long-term survival in the mitral position at 10 years
and beyond remains unclear. A comparison 5 years from
now should shed light on the subsequent effect of prosthe-
ses on long-term 15-year survival.
Although our study is limited by its retrospective nature,
our statistical methods attempt to control for most of the
bias in the assignment of valve type. Randomized trials
themselves are limited because randomization requires
stratification on many prognostic variables and thus often
leads to a selection of very specific groups of patients with
results that lack generalizability. In addition, randomization
is based on a few variables that the investigators consider
the most significant predictors of the outcome. In contrast,
propensity score analysis provides a balance of the 2 com-
pared groups with weighted effects of the covariates on the
treatment variable and thus is able to minimize the bias
relating to imbalances in the assignment of treatment type.
This study suggests that choice of biologic or mechanical
prostheses in the mitral position has little effect on survival up
to 10 years. At the present time, choice of biologic or mechan-
ical prostheses in the mitral position should be based on the
patient ability to take anticoagulation, patient preference, and
the likelihood of reoperation. Future studies should examine
whether reoperation on bioprostheses between 10 and 15 years
after the original operation adversely affects 15-year survival.
Future studies should also compare morbidity, quality of life,
and long-term care costs for patients undergoing mitral valve
replacement with mechanical or biologic prostheses.
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